- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
- BridgeBio Pharma Announces Proposed Public Offering of Common Stock
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
- BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
- BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
More ▼
Key statistics
On Thursday, BridgeBio Pharma Inc (2CL:BER) closed at 23.25, 98.72% above the 52 week low of 11.70 set on May 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.25 |
---|---|
High | 23.25 |
Low | 23.25 |
Bid | -- |
Offer | -- |
Previous close | 23.48 |
Average volume | 153.67 |
---|---|
Shares outstanding | 183.70m |
Free float | 141.03m |
P/E (TTM) | -- |
Market cap | 4.59bn USD |
EPS (TTM) | -3.95 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 07:04 BST.
More ▼